The present invention relates to a kind of 2 type Dopaminergic receptors agonists to treat the application because caused by being increased vascular endothelial growth factor (VEGF) in eye disease, is treating or preventing the retinal disease because caused by increasing Vascular permeability pressure and its angiogenesis especially with dopaminergic D2 receptor stimulating agents Cabergoline.